| Q43263618 | 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis |
| Q37694704 | A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies |
| Q100750450 | A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy |
| Q83434939 | A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study |
| Q43085409 | A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. |
| Q80479511 | ABO-incompatible allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning: close association with transplant-associated microangiopathy |
| Q54052781 | Active acute leukaemia: should transplant be offered to all patients? |
| Q83388964 | Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI-associated acute GVHD without influencing the GVL effect |
| Q46465440 | Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens |
| Q92296737 | Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT |
| Q35925072 | Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome |
| Q30399209 | Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy |
| Q49817229 | Allogeneic hematopoietic stem cell transplantation for treatment of refractory and relapsed acute myeloid leukemia: outcomes and prognostic factors |
| Q37842488 | Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations |
| Q52870483 | Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long-term outcome. |
| Q37559330 | Allogeneic stem cell transplantation in acute myeloid leukemia: establishment of indications on the basis of individual risk stratification |
| Q39002077 | Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission |
| Q87901185 | Allogeneic transplantation in primary refractory AML |
| Q39475017 | An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation |
| Q63384223 | Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse |
| Q36850764 | Blood and marrow transplantation in elderly acute myeloid leukaemia patients - older certainly is not better |
| Q89575182 | Bridging Strategies to Allogeneic Transplant for Older AML Patients |
| Q36151239 | Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a si |
| Q46244557 | Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study |
| Q46047569 | Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation |
| Q45250906 | Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG. |
| Q90788447 | Clinical outcome of FLAG-IDA chemotherapy sequential with Flu-Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes |
| Q41474323 | Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial. |
| Q34348102 | Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia |
| Q90826221 | Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis |
| Q33830964 | Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. |
| Q92451380 | Conditioning intensity and antilymphocyte globulin: towards personalized transplant strategies? |
| Q39306717 | Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia |
| Q38229633 | Conditioning regimens in acute myeloid leukemia |
| Q79370633 | Conditioning with fludarabine alone and allogeneic transplantation as a successful rescue therapy for persistent, severe iatrogenic aplasia after relapse of acute myeloid leukemia |
| Q41039704 | Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes. |
| Q45233774 | Cytogenetic risk grouping by the monosomal karyotype classification is superior in predicting the outcome of acute myeloid leukemia undergoing allogeneic stem cell transplantation in complete remission |
| Q39414681 | Cytokine Release Patterns in Mixed Lymphocyte Culture (MLC) of T-Cells with Dendritic Cells (DC) Generated from AML Blasts Contribute to Predict anti-Leukaemic T-Cell Reactions and Patients' Response to Immunotherapy |
| Q24630836 | Defining the intensity of conditioning regimens: working definitions |
| Q33781597 | Design and characterization of a polymeric MRI contrast agent based on PVA for in vivo living-cell tracking. |
| Q37624593 | Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel |
| Q43005378 | Diagnosis of Toxoplasma gondii infection after allogeneic stem cell transplant can be difficult and requires intensive scrutiny |
| Q47598339 | Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia |
| Q34167404 | Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study |
| Q86722614 | Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia |
| Q36173285 | Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies |
| Q55263365 | Efficacy and Safety of Unmanipulated Haploidentical Related Donor Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia. |
| Q91776744 | Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia |
| Q37962599 | Epigenomics in hematopoietic transplantation: novel treatment strategies |
| Q30318110 | Evaluation of BM cytomorphology after allo-SCT in patients with AML. |
| Q83682066 | Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML |
| Q40777838 | FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission |
| Q90079683 | FLAMSA-RIC for Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis |
| Q83457906 | Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia |
| Q34871703 | Factors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation |
| Q30315865 | Favorable outcome in children and adolescents with a high proportion of advanced phase disease using single/multiple autologous or matched/mismatched allogeneic stem cell transplantations. |
| Q43140221 | Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. |
| Q58565569 | Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial |
| Q64089200 | Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Bloo |
| Q43730651 | Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience |
| Q39067366 | Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant? |
| Q45172618 | Frequency and prognostic value of D alloantibodies after D-mismatched allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning |
| Q37061964 | Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML. |
| Q37267749 | Growth differentiation factor 15 contributes to cancer-associated fibroblasts-mediated chemo-protection of AML cells |
| Q90275244 | Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data |
| Q90441706 | Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial |
| Q34049208 | Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. |
| Q64117006 | Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia |
| Q37061969 | Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia. |
| Q60326486 | High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission |
| Q36032008 | Immune responses to RHAMM in patients with acute myeloid leukemia after chemotherapy and allogeneic stem cell transplantation |
| Q40583092 | Immunonutrition Is Associated With a Decreased Incidence of Graft-Versus-Host Disease in Bone Marrow Transplant Recipients: A Meta-Analysis |
| Q50923400 | Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. |
| Q83731500 | In vitro-induced response patterns of antileukemic T cells: characterization by spectratyping and immunophenotyping |
| Q41676842 | Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. |
| Q38098957 | Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies |
| Q36862461 | Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse |
| Q34185528 | Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia |
| Q36805838 | JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse |
| Q44973890 | Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non-myeloablative conditioning without T cell depletion |
| Q37943251 | Management of refractory acute myeloid leukemia: re-induction therapy or straight to transplantation? |
| Q37202615 | Minimal residual disease diagnostics in myeloid malignancies in the post transplant period |
| Q44552933 | Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia--feasibility and safety study |
| Q80514647 | Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia |
| Q54398542 | Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. |
| Q40725017 | Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy. |
| Q92268028 | National survey on total-body irradiation prior to reduced-intensity stem cell transplantation in Japan: The Japanese Radiation Oncology Study Group |
| Q34255206 | Neoplastic meningitis in patients with acute myeloid leukemia scheduled for allogeneic hematopoietic stem cell transplantation |
| Q79819148 | Outcome of allo-SCT for chronic myelomonocytic leukemia |
| Q47592938 | Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. |
| Q54509279 | Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). |
| Q53250655 | Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. |
| Q99554797 | Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation |
| Q36117062 | Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction |
| Q36668271 | Perspectives of proteomics in acute myeloid leukemia |
| Q34220717 | Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia |
| Q46909610 | Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome |
| Q43690436 | Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis |
| Q33877213 | Primary refractory acute myeloid leukaemia - in search of better definitions and therapies |
| Q84192368 | Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation |
| Q84405870 | Prognostic factors in allo-SCT of elderly patients with AML |
| Q50686421 | Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning. |
| Q89467894 | Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation |
| Q80008514 | Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation-procedures ex vivo or in vivo |
| Q40824434 | Reactivation of polyomavirus in the genitourinary tract is significantly associated with severe GvHD and oral mucositis following allogeneic stem cell transplantation |
| Q28307278 | Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia |
| Q35800814 | Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT. |
| Q43152085 | Reduced intensity conditioning prior to allogeneic stem cell transplantation in first complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk karyotype |
| Q38199623 | Relapse assessment following allogeneic SCT in patients with MDS and AML. |
| Q60917013 | Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment |
| Q53194829 | Risk Factors for Graft-Versus-Host Disease After Transplantation of Hematopoietic Stem Cells from Unrelated Donors in the China Marrow Donor Program. |
| Q37419348 | Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia |
| Q40971755 | Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation. |
| Q37510948 | Safety of conditioning agents for allogeneic haematopoietic transplantation |
| Q38406744 | Salvage therapy for acute chemorefractory leukemia by allogeneic stem cell transplantation: the Korean experience. |
| Q36612564 | Salvage therapy for relapsed or refractory acute myeloid leukemia |
| Q37216454 | Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy |
| Q51735777 | Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. |
| Q43288360 | Second unrelated cord blood transplantation using a reduced-intensity conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia |
| Q84860501 | Sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell transplantation for refractory acute lymphoblastic leukemia |
| Q40460438 | Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT. |
| Q37362718 | Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT. |
| Q37555840 | Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia |
| Q41509697 | Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma. |
| Q33397272 | Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study |
| Q39137552 | Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML. |
| Q48144263 | Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie C |
| Q49716061 | Strategies for improving the outcomes of allogeneic stem cell transplantation in patients with relapsed acute leukemia |
| Q42429593 | Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT. |
| Q86871463 | Survival and prognostic factors in Malaysian acute myeloid leukemia patients after allogeneic haematopoietic stem cell transplantation |
| Q48137892 | Suspected encephalitis with Candida tropicalis and Fusarium detected by unbiased RNA sequencing |
| Q52690439 | T-cell-depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT). |
| Q96639301 | Tandem Allogeneic Hematopoietic Stem Cell Transplantation for Salvage Treatment of Acute Myeloid Leukemia Refractory to Induction Chemotherapy: A Case Report |
| Q47124626 | Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity |
| Q28830861 | The European Hematology Association Roadmap for European Hematology Research: a consensus document |
| Q38040708 | The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach |
| Q31143348 | The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative Grou |
| Q51455474 | The proteome pattern cGvHD_MS14 allows early and accurate prediction of chronic GvHD after allogeneic stem cell transplantation. |
| Q91859903 | The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience |
| Q91045478 | Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies |
| Q90452498 | Timed sequential salvage chemotherapy for relapsed or refractory acute myeloid leukemia |
| Q47741553 | Treatment of relapsed/refractory acute myeloid leukaemia in adults |
| Q36977560 | Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant |
| Q36824553 | Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia |
| Q80148762 | [Female patient with organic psychosyndrome and neurological focal signs after immunosuppressant therapy] |
| Q35266033 | ¹⁸F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia |